PhenoPath deepens Quest’s presence in the Pacific Northwest while extending the company’s capabilities in anatomic pathology and molecular oncology
Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology and related services.
Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of the company’s Advanced Diagnostics portfolio of services. These include services, such as genetic sequencing and genomic tumor analysis, which require higher-order expertise and skill.
“Our acquisition of PhenoPath delivers on our accelerate growth strategy for advanced diagnostics,” said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. “PhenoPath has a strong record of innovation, and provides several capabilities that complement and extend our own, particularly in pathology and molecular oncology. It also deepens our presence in the Pacific Northwest.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The PhenoPath business will operate as part of AmeriPath, a wholly owned business of Quest Diagnostics. The leading provider of anatomic pathology services, AmeriPath provides high-end pathology services to many ambulatory health and surgery centers, imaging centers, clinics and physician offices, and has on-site community pathologists in more than 170 hospitals across the country.
AP and molecular oncology services are essential to diagnose many diseases, particularly cancer. In 2018, there will be an estimated 1,735,350 new cancer cases diagnosed in the United States, according to the American Cancer Society.
Additional terms of the transaction were not disclosed.
Date: October 1, 2018
Source: QuestDiagnostic
